James Barrett, Ph.D.

Jim Barrett joined NEA in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Present board memberships include CoGenesys, GlycoMimetics, Inhibitex, Inc. (NASDAQ: INHX), Iomai Corporation, Nucleonics, Inc., Peptimmune, Inc., Pharmion Corporation (NASDAQ: PHRM), Ruxton Pharmaceuticals, Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals, Targacept, and he also serves on the board of MedImmune. Prior to NEA, Jim served as Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995), President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Jim worked in various divisions of SmithKline. NEA and Jim have worked together since 1982 when he was recruited to run Bethesda Research Laboratories, which merged with Life Technologies. NEA then backed Jim at Genetic Therapy and later at Sensors for Medicine and Science. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Bradley G. Lorimier

Brad Lorimier is an independent consultant to the pharmaceutical and biotechnology industries. Mr. Lorimier has served in leadership positions in both the pharmaceutical and biotechnology industries, including as Vice President of Licensing and Vice President of Corporate Development at Johnson & Johnson and as Senior Vice President and Director of Human Genome Sciences. He is currently on the board of directors of Invitrogen Corporation, CoGenesys and Avalon Pharmaceuticals, where he is also a co-founder. Mr. Lorimier was a director of Matrix Pharmaceutical, Inc. from December 1997 to March 2002. He received his B.S. from the University of Illinois in 1967.

Steven C. Mayer

Steve Mayer is CEO and a founder of CoGenesys. Prior to joining CoGenesys, Mr. Mayer was the Executive Vice President and Chief Financial Officer of Human Genome Sciences, Inc. He joined HGS as Senior Vice President and Chief Financial Officer in September 1996, and has since served as a member of the Management Committee. While at HGS, Mr. Mayer raised over $3 billion in equity, debt, and facilities financing. Prior to joining HGS, from 1995 to 1996, he was Vice President and Chief Financial Officer of GenVec, Inc., an early-stage gene therapy company. From 1991 to 1995 he served as Vice President & Chief Financial Officer and as Senior Vice President & Chief Financial Officer of TheraTech, Inc., a leading drug delivery company. Prior to joining TheraTech, Mr. Mayer was involved in the formation of Myriad Genetics and was CFO of another early stage biotech company, NPI. He also has had experience in investment banking with Smith Barney and in corporate finance with Martin Marietta Corporation. Mr. Mayer serves on the NASDAQ Issuer Affairs Committee and on the FASB Small Business Advisory Committee. Mr. Mayer holds an MBA degree from Stanford University and a B.A. degree, cum laude, with honors in Economics from Williams College.

Charles (Chuck) Newhall

Charles (Chuck) Newhall is a Co-Founder and General Partner of NEA. His investment activities focus on healthcare services, healthcare information services and biopharmaceutical companies. His board memberships include CoGenesys, ElderHealth, Hospital Partners of America, Sensors for Medicine & Science, TargetRx, Trine Pharmaceuticals, Vela Pharmaceuticals, and Vitae Pharmaceuticals. His prior board memberships include among others, AMERIGROUP, Caremark, Chomerics, Genetic Therapy, Life Technologies, PatientKeeper, Russ Pharmaceuticals, Scandipharm, Sepracor, Surgical Health, and Zymark Corporation. He is Founder of the Mid-Atlantic Venture Association. Before co-founding NEA, Chuck was a Vice President with T. Rowe Price Associates and Vice President of their New Horizons Fund. He received his MBA from the Harvard University Graduate School of Business and his BA in English Literature with honors from the University of Pennsylvania.

Craig A. Rosen, Ph.D.

Craig Rosen is Executive Chairman, Chief Scientific Officer and a founder of CoGenesys. Prior to joining CoGenesys, Dr. Rosen was President and Chief Scientific Officer and a member of the Board of Directors for Human Genome Sciences, Inc. (HGS). Dr. Rosen was a founding scientist at HGS and from 1993-2004 held various executive positions including Chief Operating Officer and Executive Vice President of Research and Development where he was responsible for drug discovery, development and manufacturing activities. During Dr. Rosen's tenure at the company, HGS advanced 14 drugs into human clinical trials. He has also been inventor on approximately 300 issued patents and has authored over 125 scientific publications. Prior to joining HGS, Dr. Rosen was Chairman of the Department of Gene Regulation at the Roche Institute of Molecular Biology. Dr. Rosen received his Bachelor of Science and Ph.D. in Microbiology from the University of Rhode Island. Dr. Rosen has served on the Boards of Vascular Genetics, Inc. (now Corautus Genetics), the American Foundation for AIDS Research (AmFAR) and the Scientific Advisory Boards for the Institute of Human Virology and the Wistar Institute.

Michael B. Sheffery, Ph.D.

Michael B. Sheffery is a founding General Partner of OrbiMed and Co-Head of Private Equity. Dr. Sheffery was formerly Head of the Laboratory of Gene Structure and Expression at Memorial Sloan-Kettering Cancer Center. He received both his Ph.D. in Molecular Biology and his B.A. in Biology from Princeton University. Dr. Sheffery joined Mehta and Isaly in 1996 as a Senior Analyst covering the biotechnology industry. He is currently a Director of Biosynexus Incorporated, Eximias Pharmaceuticals and CoGenesys, Inc. and was formerly a Director of Biosynexus, Memory Pharmaceuticals, and NeoGenesis Pharmaceuticals.

David C. U'Prichard, Ph.D.

Dr. David C. U'Prichard currently serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries and as a Venture Partner at Red Abbey Venture Partners (Baltimore) and Care Capital LLC (Princeton). From 1997 to 1999, Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham. Prior to SmithKline Beecham, he worked for ICI/Zeneca as Executive Vice President and International Research Director. Dr. U'Prichard was instrumental in the launch of Nova Pharmaceuticals, Baltimore MD in 1983, following an academic career as Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School. Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow. He has authored more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology and co-editor of Epinephrine in the Central Nervous System. Dr. U'Prichard is Chairman of the Board of Cyclacel Pharmaceuticals Inc. and Oxagen Ltd and serves on the Board of Directors of Invitrogen Corp , SMART Biosciences, Inc. and SR Pharma PLC. Dr.U’Prichard was Chairman of the Pennsylvania Biotechnology Association from 2004-2005. Dr. U’Prichard is a consultant for Booz Allen Hamilton, is a Trustee of the International House of Philadelphia and is on the Board of the Bioethics Institute of the University of Pennsylvania.